Triple Study

Comparisons

Where it comes from

Other

Other

Highlighted claims

• The Triple Study is a prospective, multicentre, open-label, randomised, parallel-group controlled trial. — Triple-drug therapy with Goreisan, tranexamic acid and carbazochrome sodium sulfonate hydrate to prevent recurrence after chronic subdural haematoma surgery: a multicentre, randomised, controlled trial protocol
• The trial is conducted at six hospitals in Ibaraki Prefecture, Japan. — Triple-drug therapy with Goreisan, tranexamic acid and carbazochrome sodium sulfonate hydrate to prevent recurrence after chronic subdural haematoma surgery: a multicentre, randomised, controlled trial protocol
• The trial is registered as jRCTs031240007 and is scheduled from 1 May 2024 to 31 March 2028. — Triple-drug therapy with Goreisan, tranexamic acid and carbazochrome sodium sulfonate hydrate to prevent recurrence after chronic subdural haematoma surgery: a multicentre, randomised, controlled trial protocol
• The trial is open-label, but imaging outcomes are assessed by a blinded independent radiologist. — Triple-drug therapy with Goreisan, tranexamic acid and carbazochrome sodium sulfonate hydrate to prevent recurrence after chronic subdural haematoma surgery: a multicentre, randomised, controlled trial protocol
• The control group receives standard postoperative care without oral pharmacological prophylaxis. — Triple-drug therapy with Goreisan, tranexamic acid and carbazochrome sodium sulfonate hydrate to prevent recurrence after chronic subdural haematoma surgery: a multicentre, randomised, controlled trial protocol